Detalhe da pesquisa
1.
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
Lancet
; 388(10062): 2873-2884, 2016 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27863809
2.
Inferring the underlying multivariate structure from bivariate networks with highly correlated nodes.
Sci Rep
; 12(1): 12486, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864116
3.
Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
J Alzheimers Dis
; 83(3): 1017-1023, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34366349
4.
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
J Alzheimers Dis
; 75(2): 501-519, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32280089
5.
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
J Alzheimers Dis
; 72(3): 931-946, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658058
6.
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
J Alzheimers Dis
; 61(1): 435-457, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29154277